| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5645613 | Clinical Skin Cancer | 2016 | 14 Pages |
Abstract
The primary endpoint of the present trial is the percentage of patients in whom an R0 resection (microscopically radical) can be performed, as evaluated by pathologic examination. The secondary endpoints are recurrence-free survival, time to next treatment, and overall survival. Translational research will focus primarily on the assessment of treatment-induced changes in exome mutations within the tumor and changes in gene expression profiles.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Max F. Madu, E.A. Lisette Rozeman, Jos A. van der Hage, Michel W.J.M. Wouters, W. Martin C. Klop, J.V. Hans van Thienen, Christian U. Blank, John B.A.G. Haanen, Alexander C.J. van Akkooi,